ROI yields 1642.04% · ABBV yields 3.06%● Live data
📍 ROI pulled ahead of the other in Year 1
Combined, ROI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ROI + ABBV for your $10,000?
RiskOn International, Inc., through its subsidiaries, owns and operates gaming platform in the United States. It also owns and operates bitnile.com metaverse platform, a social networking community that allows users to engage and purchase digital and physical products while playing 3D immersive games. The company offers virtual markets, a graphic product that changes the appearance of characters in virtual real estate, digital art, and other collectibles; sweepstakes gaming, a gaming zone for virtual and real money prizes; building private spaces, a design option that allows users to construct and customize their dream homes or private spaces; and real and virtual concerts, a concert for users. In addition, it provides fashion, electronics, and home related goods for marketplaces; organizes competitions for users, as well as enables users to interact with individuals with socialization and connectivity related products. Further, the company offers gaming options for users, sweepstakes, and social gaming experience users. The company was formerly known as BitNile Metaverse, Inc. and changed its name to RiskOn International, Inc. in November 2023. RiskOn International, Inc. was founded in 2011 and is headquartered in San Antonio, Texas.
Full ROI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.